Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Daniel F. Alonso 1 Article
Preclinical Efficacy of [V4 Q5 ]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer
Juan Garona, Natasha T. Sobol, Marina Pifano, Valeria I. Segatori, Daniel E. Gomez, Giselle V. Ripoll, Daniel F. Alonso
Cancer Res Treat. 2019;51(2):438-450.   Published online June 1, 2018
DOI: https://doi.org/10.4143/crt.2018.040
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Control of metastatic spread of colorectal cancer (CRC) remains as a major therapeutic challenge. [V4 Q5 ]dDAVP is a vasopressin peptide analog with previously reported anticancer activity against carcinoma tumors. By acting as a selective agonist of arginine vasopressin type 2 membrane receptor (AVPR2) present in endothelial and tumor cells, [V4Q5]dDAVP is able to impair tumor aggressiveness and distant spread. Our aim was to evaluate the potential therapeutic benefits of [V4Q5]dDAVP on highly aggressive CRC disease using experimental models with translational relevance.
Materials and Methods
Murine CT-26 and human Colo-205 AVPR2-expressing CRC cell lines were used to test the preclinical efficacy of [V4Q5]dDAVP, both in vitro and in vivo.
Results
In syngeneic mice surgically implanted with CT-26 cells in the spleen, sustained intravenous treatment with [V4Q5]dDAVP (0.3 µg/kg) dramatically impaired metastatic progression to liver without overt signs of toxicity, and also reduced experimental lung colonization. The compound inhibited in vivo angiogenesis driven by Colo-205 cells in athymic mice, as well as in vitro endothelial cell migration and capillary tube formation. [V4Q5]dDAVP exerted AVPR2-dependent cytostatic activity in vitro (IC50 1.08 µM) and addition to 5-fluorouracil resulted in synergistic antiproliferative effects both in CT-26 and Colo-205 cells.
Conclusion
The present preclinical study establishes for the first time the efficacy of [V4Q5]dDAVP on CRC. These encouraging results suggest that the novel second generation vasopressin analog could be used for the management of aggressive CRC as an adjuvant agent during surgery or to complement standard chemotherapy, limiting tumor angiogenesis and metastasis and thus protecting the patient from CRC recurrence.

Citations

Citations to this article as recorded by  
  • Gastrointestinal digestion of food proteins: Anticancer, antihypertensive, anti-obesity, and immunomodulatory mechanisms of the derived peptides
    Zheng Yan, Yang Gui, Chunhong Liu, Xiaohai Zhang, Chaoling Wen, Opeyemi Joshua Olatunji, Itthanan Suttikhana, Tolulope Joshua Ashaolu
    Food Research International.2024; 189: 114573.     CrossRef
  • AVPR2 is a potential prognostic biomarker and correlated with immune infiltration in head and neck squamous cell carcinoma
    Linwei Mao, Zhiyong Pan, Wenzhi Chen, Weiqun Hu, Xiufen Chen, Huiting Dai
    BMC Medical Genomics.2023;[Epub]     CrossRef
  • Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN)
    Emelie Gezelius, Pär-Ola Bendahl, Widet Gallo, Kelin Gonçalves de Oliveira, Lars Ek, Bengt Bergman, Jan Sundberg, Olle Melander, Mattias Belting
    Cancers.2022; 14(5): 1307.     CrossRef
  • Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides
    Mladena Glavaš, Agata Gitlin-Domagalska, Dawid Dębowski, Natalia Ptaszyńska, Anna Łęgowska, Krzysztof Rolka
    International Journal of Molecular Sciences.2022; 23(6): 3068.     CrossRef
  • Identification of Hub Genes of Lung Adenocarcinoma Based on Weighted Gene Co-Expression Network in Chinese Population
    Yuning Xie, Hongjiao Wu, Wenqian Hu, Hongmei Zhang, Ang Li, Zhi Zhang, Shuhua Ren, Xuemei Zhang
    Pathology and Oncology Research.2022;[Epub]     CrossRef
  • Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy
    Luisina M. Solernó, Natasha T. Sobol, María F. Gottardo, Carla S. Capobianco, Maximiliano R. Ferrero, Liliana Vásquez, Daniel F. Alonso, Juan Garona
    Scientific Reports.2022;[Epub]     CrossRef
  • Genetic Determination of Regressive Pattern of Walker 256 Carcinosarcoma in Rats with Hypothalamic Diabetes Insipidus
    I. I. Khegay
    Bulletin of Experimental Biology and Medicine.2022; 173(4): 441.     CrossRef
  • Vasopressin Receptors in Blood Vessels and Proliferation of Endotheliocytes
    I. I. Khegay
    Russian Journal of Bioorganic Chemistry.2021; 47(4): 815.     CrossRef
  • Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy
    Sonali Sinha, Nidhi Dwivedi, Shixin Tao, Abeda Jamadar, Vijayakumar R. Kakade, Maura O’ Neil, Robert H. Weiss, Jonathan Enders, James P. Calvet, Sufi M. Thomas, Reena Rao
    Oncogene.2020; 39(6): 1231.     CrossRef
  • Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial
    Soledad Iseas, Enrique L. Roca, Juan M. O’Connor, Martin Eleta, Analia Sanchez-Luceros, Daniela Di Leo, Marcelo Tinelli, Maria L. Fara, Eduardo Spitzer, Ignacio A. Demarco, Giselle V. Ripoll, Marina Pifano, Juan Garona, Daniel F. Alonso
    Investigational New Drugs.2020; 38(5): 1580.     CrossRef
  • The Anticancer Properties of Tanshinones and the Pharmacological Effects of Their Active Ingredients
    Li Fu, Bing Han, Yang Zhou, Jie Ren, Wenzhi Cao, Gopal Patel, Guoyin Kai, Jun Zhang
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • Potential Use of Desmopressin During Hepatic Resection for Colorectal Liver Metastases*
    Juan Garona, Natasha T. Sobol, Luisina M. Solernó, Daniel F. Alonso
    Journal of Surgical Research.2019; 237: 1.     CrossRef
  • 9,721 View
  • 280 Download
  • 18 Web of Science
  • 12 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP